PHARMACOKINETICS OF HIGH-DOSE BUSULFAN IN RELATION TO AGE AND CHRONOPHARMACOLOGY

被引:154
作者
HASSAN, M
OBERG, G
BEKASSY, AN
ASCHAN, J
EHRSSON, H
LJUNGMAN, P
LONNERHOLM, G
SMEDMYR, B
TAUBE, A
WALLIN, I
SIMONSSON, B
机构
[1] UNIV HOSP UPPSALA,DEPT MED,S-75185 UPPSALA,SWEDEN
[2] UNIV LUND HOSP,DEPT PEDIAT,S-22185 LUND,SWEDEN
[3] HUDDINGE HOSP,DEPT TRANSPLANT SURG,S-14186 HUDDINGE,SWEDEN
[4] HUDDINGE HOSP,DEPT MED,S-14186 HUDDINGE,SWEDEN
[5] UNIV HOSP UPPSALA,DEPT PEDIAT,S-75185 UPPSALA,SWEDEN
[6] UNIV UPPSALA,DEPT STAT,S-75105 UPPSALA,SWEDEN
关键词
BONE-MARROW TRANSPLANTATION; ANTICANCER DRUGS; BUSULFAN; CHILDREN; LEUKEMIA; CYCLOPHOSPHAMIDE; CHEMOTHERAPY; DISPOSITION; INDUCTION; ADULTS;
D O I
10.1007/BF00689702
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Busulphan levels in plasma were measured in 27 patients during conditioning therapy (1 mg/kg x 4 for 4 days) before bone marrow transplantation. The mean minimal concentration found in children aged < 5 years (237 ng ml-1) was lower than that observed in adults or older children (607 and 573 ng ml-1, respectively). The AUC for the last dose was significantly lower in young children (2,315 h ng ml-1) than in adults or older children (6,134 and 5,937 h ng ml-1, respectively). The elimination half-life for the last dose in young children was shorter (2.05 h) than that in either adults (2.59 h) or older children (2.79 h). When the AUC was normalized for body surface area, the difference between young children and the other groups was smaller but remained statistically significant. The total body clearance was significantly higher in young children (7.3 ml min-1 kg-1) as compared with both older children and adults (3.02 and 2.7 ml min-1 kg-1, respectively). The plasma levels of busulphan showed circadian rhythmicity, especially in young children. The concentration measured during the night in some patients was up to 3-fold that observed during daytime. We conclude that the busulphan dosage for children must be reconsidered and that further studies are urgently needed to develop an optimal therapy.
引用
收藏
页码:130 / 134
页数:5
相关论文
共 22 条
  • [11] PHARMACOKINETIC AND METABOLIC STUDIES OF HIGH-DOSE BUSULFAN IN ADULTS
    HASSAN, M
    OBERG, G
    EHRSSON, H
    EHRNEBO, M
    WALLIN, I
    SMEDMYR, B
    TOTTERMAN, T
    EKSBORG, S
    SIMONSSON, B
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (05) : 525 - 530
  • [12] HOBBS JR, 1986, BONE MARROW TRANSPL, V1, P201
  • [13] CIRCADIAN TIMING OF CANCER-CHEMOTHERAPY
    HRUSHESKY, WJM
    [J]. SCIENCE, 1985, 228 (4695) : 73 - 75
  • [14] LEVI F, 1985, CANCER TREAT REP, V69, P1443
  • [15] CHRONOPHARMACOLOGY
    MARKS, V
    ENGLISH, J
    AHERNE, W
    ARENDT, J
    [J]. CLINICAL BIOCHEMISTRY, 1985, 18 (03) : 154 - 157
  • [16] PEDIATRIC DRUG DOSING - BODY-WEIGHT VERSUS SURFACE-AREA
    MAXWELL, GM
    [J]. DRUGS, 1989, 37 (02) : 113 - 115
  • [17] CHRONOBIOLOGY - ITS IMPORTANCE IN CLINICAL MEDICINE
    MINORS, DS
    [J]. CLINICAL SCIENCE, 1985, 69 (04) : 369 - 376
  • [18] MARROW TRANSPLANTATION FOR ACUTE NONLYMPHOCYTIC LEUKEMIA AFTER TREATMENT WITH BUSULFAN AND CYCLOPHOSPHAMIDE
    SANTOS, GW
    TUTSCHKA, PJ
    BROOKMEYER, R
    SARAL, R
    BESCHORNER, WE
    BIAS, WB
    BRAINE, HG
    BURNS, WH
    ELFENBEIN, GJ
    KAIZER, H
    MELLITS, D
    SENSENBRENNER, LL
    STUART, RK
    YEAGER, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (22) : 1347 - 1353
  • [19] VASSAL G, 1989, CANCER CHEMOTH PHARM, V24, P386
  • [20] WANG YM, 1979, CANCER TREAT REP, V63, P405